Caption Management Adds $22M in Corcept Therapeutics Incorporated ($CORT)
Key Points
- Wall Street's consensus rating on $CORT is Strong Buy and an average price target of $88.00.
- $CORT last traded around $82.91.
Caption Management acquired a new position in Corcept Therapeutics Incorporated ($CORT), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 260,000 shares of Corcept Therapeutics Incorporated. Caption Management's holdings in Corcept Therapeutics Incorporated were worth $21.56 million as of its most recent filing.
Corcept Therapeutics Incorporated ($CORT) Stock
Corcept Therapeutics Incorporated Earnings
Analysts Set New Price Targets
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.